Navigation Links
Monarch Labs to Demonstrate Maggot Therapy at Diabetic Limb Salvage Conference

IRVINE, Calif., Sept. 22 /PRNewswire/ -- Monarch Labs LLC, the exclusive supplier of Medical Maggots(TM) in the United States, announced today that its Laboratory Director and co-founder, Dr. Ronald Sherman, will attend the Diabetic Limb Salvage conference in Washington, DC, from September 24 to September 26. At Monarch's table display, Dr. Sherman will exhibit the company's Medical Maggots(TM) product (disinfected Phaenicia sericata larvae) and demonstrate this natural therapy to meeting participants.

Maggot therapy is the intentional introduction of live, disinfected maggots (fly larvae) into non-healing human and animal wounds for the purposes of selectively cleaning out only the dead tissue in the wounds to allow healing. Medical Maggots(TM) were cleared for marketing by the U.S. Food and Drug Administration in 2004, and since that time this method of treating non-healing wounds has steadily increased.

"Maggot therapy represents a revolutionary, natural and cost-effective medical device for cleaning many types of wounds," Sherman said. "In regular use in over 20 countries around the world, it has proven to be a safe and effective treatment. My goal in attending this conference is to educate more health care practitioners about the use of maggot therapy for their diabetic foot ulcer patients."

About 600,000 diabetics get foot ulcers every year nationwide, and traditional medical practices can cost up to $8,000 to treat such wounds, according to reports. Poor blood flow in the lower legs makes those ulcers difficult to heal.

Limb-salvage experts say many of the 80,000-plus amputations of toes, feet and lower legs that diabetics undergo each year in the U.S. are preventable, and that foot amputations alone can cost up to $30,000. Maggot therapy can be used for many types of diabetic foot ulcers. In recently published studies, nearly half of the wounds in diabetics scheduled for amputation were healed with maggot therapy, and amputation was avoided.

"When maggot therapy is used before the wounds progress to the point that amputation may be unavoidable, the success is even greater," Sherman said. "That is why we remind therapists not to hold off using maggot therapy as though it is a last resort. Patients shouldn't have to waste weeks, months or even years before they finally receive maggot therapy, all the while suffering from their chronic, limb-threatening wounds."

Medical Maggots(TM) also offer a much more cost-effective and natural way of treating these wounds. A vial of Medical Maggots(TM) sufficient for a single course of maggot therapy costs about $100 and the related dressings cost about $20. Most patients require no more than two or three treatments.

In addition, health care insurers are increasingly reimbursing patients who use maggot therapy. In September 2008, the American Medical Association, in collaboration with the Centers for Medicare and Medicaid Services, issued reimbursement coding guidelines for medicinal maggots and maggot therapy.

The Diabetic Limb Salvage conference, sponsored by Georgetown University Hospital/MedStar, will be held at the JW Marriott Pennsylvania Avenue in Washington, DC, from September 24 to 26. The education program, which is expected to attract 1,100 attendees, will be presented by more than 60 nationally known diabetic limb salvage experts.

About Medical Maggots(TM)

Medical Maggots(TM) (disinfected Phaenicia sericata larvae) are a proprietary strain of living fly larvae that are raised and processed in specialized facilities. They represent the first living organism ever allowed by the U.S. FDA for production and marketing as a prescription-only medical device. Medical Maggots(TM) are used for debriding non-healing necrotic skin and soft tissue wounds, including pressure ulcers, venous stasis ulcers, neuropathic foot ulcers and non-healing traumatic or post surgical wounds.

About Monarch Labs

Monarch Labs is a life sciences company that researches, develops and commercializes innovative and proprietary wound care products. Monarch's lead product is Medical Maggots(TM), the only maggots allowed for marketing in the United States as a medical device. In March 2009, Monarch launched the first wound dressing in the U.S. specifically designed to make maggot therapy easier and quicker to administer. The dressing has been cleared by the FDA for manufacturing and marketing under the trade name LeFlap(TM). For more information, visit

SOURCE Monarch Labs LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Hitachi Medical Systems and Monarch Medical Announced as Co- Title Sponsors of the Health Connect Partners 2009 Fall Radiology and Imaging Conference
2. Varian Medical Systems to Develop Interface Between the ARIA(TM) Oncology Information System and the Monarch250(TM) Proton Radiotherapy System From Still River Systems
3. MitraClip(R) Therapy Data Demonstrate Significant Reduction in Mitral Valve Annulus Dimensions in High-Risk Patients With Functional Mitral Regurgitation
4. MitraClip(R) Therapy Data Demonstrate Significant Left Ventricular Reverse Remodeling in Patients With Sustained Reduction of Mitral Regurgitation
5. TAXUS(R) Liberte(R) Stent Continues to Demonstrate Significant Improvements Over TAXUS(R) Express(R) Stent in Small Vessels and Long Lesions
6. New type of sirolimus-eluting stent demonstrates superior results
7. Steelbox Demonstrates Open Video Framework with SRI International and Telindus Surveillance Solutions
8. PLC Medical Systems to Demonstrate RenalGuard(R) at TCT 2009, Building on Success at ESC 2009
9. Study Demonstrates That QVAR(R) is More Cost-Effective Than Other Inhaled Corticosteroid (ICS) Asthma Therapy Options
10. Research Demonstrates that HerbalSciences Proprietary Elderberry Extract Prevents in Vitro H1N1 Influenza Infection
11. Sparta Systems Demonstrates Growth in Asia-Pacific Region
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap ... and Dr. Tucker Bierbaum with Emergency Medicine at St., Joseph Health System’s ... STEMI and Sepsis conditions present in similar ways and require time-critical intervention to avoid ...
(Date:11/26/2015)... ON and Cambridge, ON (PRWEB) , ... November ... ... today the availability of a real-time eReferral system for diagnostic imaging in the ... ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic medical ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare ... participated in the 61st annual Employee Benefits Conference. The Employee Benefits Conference was ... November 8th through Wednesday, November 11th, 2015. The conference was held at the ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... Water For Empowerment ™ attracts volunteers together who want to combine talents ... women as key stakeholders in the process. The non-profit launched its first major ...
(Date:11/25/2015)... ... 2015 , ... Dr. John Pierce, Medical Director at the Ageless Forever clinic ... the Capillus272™ Pro laser therapy cap. FDA cleared for safety and efficacy, the Capillus272 ... need for surgery, prescription pills, or topical foams. , “Capillus272™ Pro is a ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... the "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... report to their offering. --> Research ... addition of the "Self Administration of High ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Cell Surface Marker ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/25/2015)... Nov. 25, 2015  Amgen (NASDAQ: AMGN ) ... (BLA) with the United States ... a biosimilar candidate to Humira ® (adalimumab). Amgen ... submitted to the FDA and represents Amgen,s first BLA ... E. Harper , M.D., executive vice president of Research ...
Breaking Medicine Technology: